The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.

ABSTRACT: The B cell receptor (BCR) signaling pathway is functional and has critical cell survival implications in B cell malignancies, such as chronic lymphocytic leukemia (CLL). Orally administered small molecule tyrosine kinase inhibitors of members of the BCR signaling pathway have proven to be transformational in treatment of CLL. The first-generation inhibitor, ibrutinib, covalently binds to the C481 amino acid of Bruton's tyrosine kinase (BTK), thereby irreversibly inhibiting its kinase activity, and interferes with the biology of the cells, ultimately resulting in CLL cell death and therapeutic response. Remissions are not deep to the point of considering discontinuation for most patients, but BTK-inhibitor-based therapy provides exceptional long-term disease control with continuous treatmen

SUBMITTER: Tambaro FP 

PROVIDER: S-EPMC8565990 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature